Objective Structured antiretroviral treatment interruption (STI) has been advocated as a therapeutic strategy for HIV-1 infection. We report initial observations of cerebrospinal¯uid (CSF) HIV-1 infection in ®ve patients undergoing serial lumbar punctures (LPs) during STI undertaken following virological failure.
Introduction
Despite the remarkable impact of highly active antiretroviral therapy (HAART) on the course of HIV-1 infection, there remain important limitations to its long-term ef®cacy. Many patients develop antiviral drug resistance, and viral eradication now appears a distant prospect [1±8] . Structured treatment interrup-tion (STI) has been proposed as a strategy to prolong the effectiveness of antiviral therapy [9±14] . For those experiencing virological failure, interruption of treatment may allow drug-susceptible (`wild-type') virus to overgrow resistant variants, thereby restoring therapeutic susceptibility in preparation for re-initiation of therapy. In patients with sustained HIV-1 suppression, STI has been advocated as a way to boost antiviral immunological responses, and as a consequence increase the likelihood of longer lasting viral suppression. Treatment interruption also affords patients a respite from the rigors of strictly adhering to a medication regimen. However, the effect of STI on potential viral reservoirs in chronically infected individuals is unknown.
Sampling cerebrospinal¯uid (CSF) provides an accessible window to an important sequestered tissue compartment [15] . We performed serial lumbar punctures (LPs) to assess the effects of STI on CSF HIV-1 infection and host responses. We report the results of initial observations from ®ve patients which show that this therapeutic strategy can be accompanied by dynamic changes in CSF infection and lymphocyte traf®c that are not appreciated by monitoring blood or patients' symptoms alone.
Methods

Study protocols and lumbar punctures
Patients participated in a University of California San Francisco (UCSF) Committee on Human Research (CHR)-approved protocol evaluating the CSF responses to changes in HAART, including STI. Repeated LPs with accompanying blood sampling were performed at approximately 3±6 week intervals over the scheduled 12 weeks of treatment interruption. Additional LPs were performed if participants continued off therapy after 12 weeks. Baseline LPs for all participants were carried out within 2 weeks before stopping therapy, and the results carried forward as day 0. CSF sampling was performed as previously described [16] .
Laboratory methods
Cell-free CSF and plasma HIV-1 RNA levels were measured using the Amplicor HIV-1 Monitor assay (Roche Diagnostic Systems, Inc., Branchburg, New Jersey, USA) in all but one patient. Samples with viral loads below 500 copies/ml were re-assessed using the Ultra Sensitive modi®cation of the Monitor assay with a dynamic range down to 50 copies/ml and a detection limit of approximately 20 copies/ml; results below this were assigned a value of 19 copies/ml. In the exception, patient 6001, HIV-1 RNA levels were determined using the bDNA assay (Quantiplex, Version 3.0; Chiron, Emeryville, California, USA) with a lower detection limit of 50 copies/ml. Paired CSF and plasma specimens from each patient were run in batch. Antiviral drug resistance was assessed by both phenotypic and genotypic analyses. Phenotypic resistance was measured for all approved antiretroviral drugs using the PhenoSense TM HIV assay (ViroLogic, South San Francisco, California, USA) with results reported as foldchange in the 50% inhibition concentration (IC 50 ) relative to a wild-type virus reference standard [17] . Genotypic analysis of drug resistance mutations in reverse transcriptase (RT) and protease inhibitor (PI)-resistant used an automated dye-primer cycle sequencing method based on the TruGene TM HIV-1 drug resistance kit (Visible Genetics, Inc., Toronto, Canada) with results compared to consensus NL4-3 sequence.
Routine CSF assessments included CSF white blood cell (WBC) and differential counts, and total protein determination; the ratio between CSF and serum albumin (3 10 À3 ) was used as an index of integrity of the blood±brain barrier to albumin and compared to age-adjusted norms from the literature. [18] . Participants also underwent standardized neurological assessments, including AIDS dementia complex (ADC) staging [19] and brief quantitative neurological performance testing incorporating four tasks and yielding an aggregate scaled z-score (QNPZ-4) [20] .
Results
Participants
The baseline characteristics of the ®ve male patients are summarized in Table 1 . Four patientts (6001, 6004, 6005 and 6006) were recruited from a larger CHRapproved study investigating the systemic consequences of STI in individuals experiencing virological failure [14] . The ®fth patient, 4026, was studied in the context of an unanticipated treatment interruption preceding a longitudinal study of the kinetics of CSF viral reduction following new or changed therapy. The median CD4 T-lymphocyte count at the start of STI was 196 3 10 6 cells/l, whereas pre-therapy nadir CD4 counts were all lower than 200 3 10 6 cells/l. All were highly experienced and had been classi®ed clinically as virological failures with plasma HIV-1 RNA concentrations . 2500 copies/ml for more than 6 months. The median HIV-1 RNA was 4.29 log 10 copies/ml in plasma and 2.36 log 10 copies/ml in CSF with a median plasma : CSF ratio (pVL : cVL; log 10 copies plasma HIV-1 RNA minus log 10 copies CSF HIV-1 RNA) of 1.71 log 10 copies/ml (range, 1.09±3.04). Baseline CSF cell counts were normal in all, although the CSF total protein was elevated in four and the albumin ratios within the normal range in all but one (6005). Four patients were neurologically normal (ADC Stage 0), whereas one was diagnosed as ADC Stage 1 (4026). QNPZ-4 scores substantiated this classi®cation in the four in which formal testing was performed; the three normal individuals scored near or above 0.0 whereas patient 4026 exhibited impaired performance with a QNPZ-4 score of -1.16. One additional individual (designated 6002) was studied under the STI CSF protocol. As he stopped only one medication, indinavir, but continued treatment with zidovudine and lamivudine, the details of his results are omitted from this report. He experienced minimal change in his plasma viral load (baseline 10 265 copies/ml HIV-1 RNA), and his CSF HIV-1 remained below or at the limit of detection and hence too low to consistently analyze by either phenotypic or genotypic methods. He also exhibited normal CSF cell counts throughout 12 weeks of STI.
Changes in HIV-1 RNA Figure 1 shows the changes in plasma and CSF HIV-1 RNA concentrations during the period of STI. Patient 6001 exhibited little change in either plasma or CSF viral loads, and his pVL : cVL remained constant (median difference of 1.65 log 10 copies/ml between the two¯uids, with a range of 1.58 to 1.71). In the remaining four patients, increases in the plasma HIV-1 viral load were variable, but in each case the CSF HIV-1 RNA concentrations rose more rapidly and to a proportionally greater extent. This resulted in a tenfold reduction of the pVL : cVL, from a median baseline value of 2.11 log 10 copies/ml (range, 1.09±3.04) to 1.16 log 10 copies/ml (range, 0.13±1.79) at the last sampling point. In three cases there appeared to be redivergence of these ratios toward the end of the study interval, away from a point of minimal difference (the median minimal pVL : cVL for the four patients was 0.29 log 10 copies/ml (range, 0.03±1.58).
CSF cell counts and neurological status
Three patients (6004, 6005 and 4026) with increases in CSF viral loads also developed substantial CSF lymphocytic pleocytosis, with peak WBC counts of 46, 46 and 31 3 10 6 cells/l, respectively (. 90% lymphocytes) ( Fig. 1 ). Small changes in the CSF cell counts in the other two patients occurred at the peak of their CSF viral loads, raising the possibility that subthreshold increases in lymphocytes (from below the linear range of routine CSF cell counts) might also have developed in them. CSF cell and viral changes were entirely asymptomatic; none of the participants experienced headache, stiff neck or other neurological symptoms. Likewise, examinations remained unchanged, and in the four who underwent serial QNPZ-4 testing, there was no decline in performance (not shown). Both CSF total protein (mean increase 10.4 mg/dl, 2.9 mg/dl SD) and the CSF : serum albumin ratio (mean increase 0.78, SD 0.27) rose during the STI period. The plasma: CSF ratio log 10 plasma HIV-1 RNA copies/ml À log 10 CSF HIV-1 RNA copies/ml.
Antiviral drug susceptibility
Phenotypic susceptibility pro®les for the drugs in each patient's pre-STI treatment regimen are plotted in Figure 1 . Baseline drug susceptibility varied among individuals: patient 6001 had nearly 100-fold decreases in susceptibility to all three drugs in his pre-STI regimen; 6004 and 6005 had decreased susceptibility (. 10-fold resistance) to two of three drugs in their regimens; and 6006 and 4026 had decreased susceptibility to only one of their prescribed drugs. In only one specimen (baseline CSF of 6005) was the HIV-1 concentration too low to amplify for phenotypic testing. Susceptibility pro®les were nearly identical in paired CSF and plasma samples at baseline and throughout the course of STI. Fold-changes in IC 50 values were within 2.5-fold of each other for 98.7% of the 315 paired CSF-plasma sample comparisons carried out in the course of evaluating susceptibilities to 15 drugs at each time interval for the ®ve patients.
Following treatment interruption, CSF and plasma viruses changed from drug-resistant to more drugsusceptible phenotypes in all ®ve patients. These changes in drug susceptibility occurred simultaneously in CSF and plasma after an initial delay following treatment interruption. Moreover, where major reversions in susceptibility to more than one drug developed, these also occurred during the same time interval. The mean time of change, estimated by using the half-way point within the assessed interval of the change, was 61.2 (AE 26.2, SD) days after interruption. The increases in CSF viral load occurred before or during this reversion interval. After reversion to a more drug-susceptible phenotype, CSF viral loads either leveled or decreased (resulting in the previously discussed late widening of the pVL : cVL). Patient 6001 was the only participant with high-level resistance to all three drugs in his regimen and experienced the smallest increase in viral load among the study patients.
The RT and PI-resistant genotypes (Table 2 ) not only were consistent with the phenotypic pro®les for all ®ve patients, but showed concordance in the mutations between the matched CSF and plasma samples. Multiple drug resistance mutations were present in the CSF and plasma at baseline in all patients. In four of ®ve patients, multiple resistance mutations present at baseline disappeared simultaneously following treatment interruption, indicating replacement of the baseline drug-resistant virus with a drug-sensitive viral variant. Phylogenetic analysis of PI-resistant codons 4±99 and RT codons 41±250 indicated no evidence of viral compartmentalization between CSF and plasma in any of the individuals at any time point. Hence, both genotypic and phenotypic data indicate that the drugresistant viral variants predominating at baseline ®rst expanded and then were superseded in both CSF and plasma during treatment interruption.
Discussion
The eventual role of STI in the long-term management of HIV-1 infection remains to be de®ned. The ®ndings in this preliminary study provide a unique view of virus exposure and altered lymphocyte traf®c during STI within an anatomically-sequestered body compartment, the leptomeninges, as re¯ected in its¯uid contents, the CSF. Four of ®ve patients experienced a steeper and proportionally greater rise of the HIV-1 concentration in CSF than in plasma, with consequent reduction in the pVL : cVL, over the course of STI. The increase in HIV-1 RNA in both compartments following treatment interruption suggests that despite`virological failure' as judged by blood analysis, the prior treatment was indeed having a salutary effect. Plasma viral load was partially suppressed, and there was an even greater suppressive effect on infection in the CSF. In all ®ve participants, the virus populations in both compart- In patient 6006, adefovir is omitted from the ®gure, but values were near 1.0 for all points in both¯uids. 3TC, lamivudine; ZDV, zidovudine; d4T, stavudine; ddI, didanosine; ABC, abacavir; EFV, efavirenz; RTV, ritonavir; IDV, indinavir; NFV, nel®navir. For two of the drugs, maximum drug resistance values were obtained in more than one patient (values were above the maximum IC 50 concentration that is measurable in the assay) and plotted as such: 3TC, 300-fold; EFV, 320-fold. ments underwent simultaneous reduction of resistance following interruption of therapy, probably re¯ecting overgrowth by more ®t, drug-sensitive HIV-1.
A striking lymphocytic pleocytosis, with peak WBC counts between 31 and 46 3 10 6 cells/l, accompanied the increases in CSF HIV-1 RNA in three patients. This provides further evidence of a biological effect of partially suppressive treatment in the face of drug resistance; in this case the suppression of lymphocyte traf®c into or proliferation within the leptomeninges. The development of overt pleocytosis in these three patients and the suggestion of small increases in WBCs in the other two accompanying the rise in CSF viral load, also provides further evidence linking CSF lymphocytosis with higher CSF viral loads and smaller plasma : CSF ratios. This relationship has also been noted in cross-sectional observations [21, 22] and agrees with our own broad experience. Additionally, we have found that in viremic patients with CSF pleocytosis not attributable to other causes, the elevated cell counts resolve following initiation of HAART [16] . The current study provides a complementary observation ± cessation of HAART led to an increase in CSF cells and virus. The concomitant increases in CSF protein and CSF : serum albumin ratios also show that STI was accompanied by alteration of the blood±brain or blood±CSF barrier to protein.
Although the disproportionate rise in CSF viral load is probably linked to the increase in CSF lymphocytes, the nature of the interaction is uncertain. Two hypotheses can be suggested to explain the increase in CSF lymphocytes and its relationship to the CSF viral load. A push hypothesis proposes that resurgent systemic infection (even if not clearly evident from plasma sampling) augments lymphocyte activation, leading to non-antigen-speci®c entry of lymphocytes (including CD4 T lymphocytes) into tissues, including the nervous system [23] . As some of these cells are infected, they can release virus into the CSF. Speci®cally, this hypothesis proposes that lymphocyte in¯ux, containing virus-infected cells, causes the increase in CSF HIV-1. The recent observation of increased numbers of activated lymphocytes in the lymph nodes of patients undergoing STI [24] supports this hypothesis, and the pleocytosis might be viewed teleologically as a host effort to defend extra-vascular tissue compartments as CD8 T-lymphocytes participate in this pleocytosis [25] .
Conversely, a pull hypothesis proposes that interruption of treatment-related suppression of local nervous system infection and subsequent increase in the viral burden, recruits lymphocytes into the CSF. In this second scenario, the in¯ux of lymphocytes is a secondary response to local infection, and does not contribute to elevated HIV-1 RNA in the CSF. Possibly both of these mechanisms contribute and, indeed, reinforce one another.
In all ®ve participants, phenotypic drug susceptibility pro®les were highly concordant between CSF and plasma samples obtained at the same time throughout the course of the study. When drug susceptibility was restored, it occurred in parallel in both¯uids. Moreover, genotypic analysis showed that the similar phenotypes within individuals were associated with identical mutation patterns. These observations strongly suggest ongoing interchange between blood and CSF rather than independent evolution of virus strains in the two compartments in these patients. Thus, the predominating type of CSF infection in this setting is probably the transitory rather than more autonomous type [16, 26] . The high CSF lymphocyte counts probably facilitate this rapid interchange between blood and CSF. Infection in this setting may differ from that predominating in patients with low blood CD4 cells and chronic CSF infection in whom slower CSF than plasma responses to therapy suggest the predominance of more autonomous infection.
Earlier in the epidemic, development of meningoencephalitis was reported in some patients upon stopping zidovudine monotherapy. It is possible that these early observations provide precedent for the ®ndings in our patients, although in the most detailed report of this phenomenon, Helbert and colleagues described recrudescence or exacerbation of ADC without pleocytosis after patients stopped zidovudine monotherapy [27] . None of the individuals in the current study developed symptoms or signs of meningitis, or indeed any other changes in neurological status as assessed by neurological history, physical examination and QNPZ-4 scores. This may imply that the perturbations in virus and lymphocyte exchange between blood and CSF in this particular setting are without clinical consequences, and therefore clinically benign. However, this study included only a small number of patients who were not severely immunosuppressed and who were, with one exception, neurologically normal, and the period of STI and subsequent follow-up may have been too short to witness development of more serious sequelae. Hence, the potential neurological implications of resurgence of virus and associated in¯ammation in the CSF, or in parallel within the brain, remain uncertain, and it is possible that neurological impairment would be more likely in individuals with active ADC or who harbour different, more`neuropathic' viral strains. The lack of brain or meningeal disturbance in our patients who experienced CSF viral recrudescence and pleocytosis may be due to the character of their viruses, to limited macrophage infection or activation, or to the absence of neurotoxic cytokine production in this setting [28] . The benign clinical course in our patients underscores the fact that development of CSF HIV-1 infection does not, in isolation, predict development of HIV-related neurologic disorders, including ADC.
If suppression of local infection can be achieved in the brain, as in the CSF, HAART may have substantial therapeutic bene®t for ADC despite continued viremia. This bene®t may relate to compartment-speci®c suppression of HIV-1 replication, which may be due to tissue-speci®c differences in drug ef®cacy, altered tropism or ®tness of drug-resistant viruses, or other unde®ned factors.
